This section is intentionally extended given the central role of safety data (and its absence) in Fadogia's verdict profile.

Common (>10% of regular users by community data and forum reports):

• Liver-enzyme elevations on routine bloodwork — community-aggregate 9/110 dopamine.club Fadogia users flag "liver concern"; forum-level reports describe ALT/AST elevations of 1.5-3× ULN after 4-12 weeks of use, normalizing on discontinuation. Mechanism (rat-data-inferred): lipid peroxidation of hepatocyte plasma membranes (Yakubu 2009). No published human hepatotoxicity threshold dose exists.
• Subjective "nothing happening" — meaningful fraction of users report no perceptible effect after 4-8 weeks at 600 mg.
• Loss-of-effect (tolerance) after 8-12 weeks — consistent with HPG-axis adaptation to the LH-stimulating signal (if that mechanism is real in humans).

Less common (1-10% in community data):

• Sexual side effects — paradoxical anorgasmia, erectile dysfunction, reduced libido — 5/110 dopamine.club reports. This is the opposite of the marketed effect and often emerges in week 6-12; consistent with HPG-axis suppression secondary to elevated T → aromatization to estradiol → negative feedback at the pituitary, OR direct testicular toxicity following the Yakubu 2008 rat pattern.
• Anxiety — 5/110 reports. Mechanism unclear; may relate to elevated T → behavioral effects or to estradiol shifts.
• Emotional blunting / "robot mode" — 6/110 reports. Mechanism uncharacterized.
• Insomnia — 3/110 reports. Mechanism uncharacterized.
• Fatigue (during cycle-off) — 3/110 reports. Consistent with transient post-cycle HPG-axis recovery — if Fadogia genuinely suppressed the user's endogenous T production during the on-cycle, the off-cycle would see a transient slump until LH/FSH normalize.

Rare-serious (case-report tier, < 1% incidence in published cases — but the published-case base is tiny):

• Fatal multi-organ failure (Coalson et al. 2025, AJRCCM 211:A3862) — 51yo M, biventricular failure + ARDS + DIC, fatal, on Fadogia + AAS + anastrozole + TMG. Fadogia not isolated causally but flagged. First published fatality case in the Fadogia literature.
• Hepatocellular injury in joint-use with Tongkat Ali — Kaliounji 2024 case was Tongkat-only but co-use is the dominant stack pattern (74/110 dopamine.club).
• Irreversible testicular damage — rat-only at 50-100 mg/kg / 28 days, but the dose range converts by BSA to ~300-600 mg in a 60-70kg human, overlapping the supplemental-use range. No human reproductive-toxicity follow-up data has been published despite 4+ years of widespread biohacker use.
• Possible interactions with concurrent AAS or aromatase inhibitors — Coalson 2025 case is the only published example; mechanism uncharacterized but the combination is logically high-risk (multiple T-axis perturbations + supplement hepatotoxicity).

Specific watch periods:

• Weeks 1-4: Baseline LFTs (ALT, AST, GGT, alkaline phosphatase) + renal panel (BUN, creatinine) before starting. If any baseline elevation, do not start.
• Weeks 4-8: Repeat LFTs + renal panel. Any ALT/AST rise >1.5× ULN → discontinue immediately and recheck in 4 weeks. Any creatinine rise >0.3 mg/dL → discontinue.
• Weeks 8-12: Total + free T + LH + FSH + estradiol-sensitive assay + SHBG to assess whether endogenous T axis is responding or being suppressed. Hematocrit + CBC to mimic AAS-monitoring conservatism. PSA if >30.
• Months 3-6: Sexual side-effect screen (libido, morning erections, orgasm capacity), depression/anxiety screen, lipid panel (Fadogia may alter HDL/LDL like other androgenic herbs).
• Cycle-off (weeks 0-4 post): Watch for HPG-axis-recovery-related fatigue, mood lability, libido dip; resolves spontaneously in 2-6 weeks if mild.
• Lifetime: Cumulative-exposure monitoring is uncharacterized. Whether 5 years of intermittent Fadogia exposure has any latent effect on testicular function, prostate, or liver is unknown.

Contraindication summary:

• Active or recent AAS cycle — hard block (Coalson 2025 case).
• Aromatase inhibitor use (anastrozole, letrozole, exemestane) — hard block in combined supplemental context (Coalson 2025 case).
• Concurrent Tongkat Ali at moderate-to-high doses — strong caution; additive hepatotoxic load (Kaliounji 2024 + community-signal liver concerns).
• Baseline liver disease (any), ALT/AST elevated, hep B/C carrier, known fatty liver — hard block.
• Baseline renal impairment, creatinine elevated, GFR < 60 — hard block.
• Prostate cancer history or BPH with significant symptoms — hard block (T-elevating compound; PSA monitoring inadequate substitute for caution).
• Cardiovascular disease, recent MI, uncontrolled HTN — strong caution.
• Untested young men with no documented low T — strong caution; no realistic upside, full downside exposure.